
VALIRX PLC — Investor Relations & Filings
ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Change of Registered Office | 2026-03-31 | English | |
| ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | |
| ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | |
| Director/PDMR Shareholding | 2026-03-04 | English | |
| ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | |
| Exercise of Warrants | 2026-01-19 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 33109023 | Change of Registered Office | 2026-03-31 | English | ||
| 33045657 | ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | ||
| 33018480 | ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | ||
| 32875259 | Director/PDMR Shareholding | 2026-03-04 | English | ||
| 32859834 | ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | ||
| 13006423 | Exercise of Warrants | 2026-01-19 | English | ||
| 34556027 | Replacement: Evaluation and Transfer Agreement | 2026-01-09 | English | ||
| 34555998 | New Evaluation and Material Transfer Agreement | 2026-01-09 | English | ||
| 34555958 | Holding(s) in Company | 2026-01-08 | English | ||
|
2025
6 filings
| |||||
| 9347356 | Holding(s) in Company | 2025-12-05 | English | ||
| 8576672 | Holding(s) in Company | 2025-11-24 | English | ||
| 8558646 | Holding(s) in Company | 2025-11-24 | English | ||
| 8482575 | Result of GM & Issue of Equity | 2025-11-20 | English | ||
| 8295975 | Holding(s) in Company | 2025-11-13 | English | ||
| 8166114 | Holding(s) in Company | 2025-11-10 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for VALIRX PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
OS Therapies Inc
Clinical-stage immunotherapy company developing treatments …
|
OSTX | US | Professional, scientific and te… |
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
VALIRX PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7998/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7998 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7998 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7998 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7998}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for VALIRX PLC (id: 7998)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.